Cartalax is a bioregulators research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Cartalax (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed from research into peptide fractions of cartilage tissue. As part of the peptide bioregulator research program originating in Russian gerontology, it represents the minimal peptide sequence proposed to encode cartilage-specific gene regulatory activity — the concept that tissue-derived short peptides can interact with chromatin and regulate the expression of genes relevant to the tissue from which they are derived. Cartalax research focuses on chondrocyte function, extracellular matrix (ECM) maintenance, and cartilage biology.
Research has examined cartalax in the context of articular cartilage degeneration models and chondrocyte culture systems. Studies have assessed its effects on proteoglycan synthesis, type II collagen expression, and matrix metalloproteinase (MMP) activity — the biochemical markers of cartilage anabolic versus catabolic balance. In aged rodent models, cartalax has been studied for effects on articular cartilage histomorphometry and chondrocyte survival following experimental joint stress. Proposed mechanisms involve transcription factor binding and epigenetic regulation of ECM-related gene promoters in chondrocytes.
PeptidesFromChina.co supplies Cartalax as a lyophilized powder at 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis accompanies every batch. All products are for laboratory research use only and are not for human consumption.
| Chemical Class | Synthetic tetrapeptide bioregulator (cartilage origin) |
|---|---|
| Synonyms | Ala-Glu-Asp-Pro, AEDP tetrapeptide, cartilage bioregulator peptide |
| Sequence | Ala-Glu-Asp-Pro |
| Amino Acids | 4 |
| Research Areas | Cartilage biology, chondrocyte research, ECM regulation, joint aging models, proteoglycan synthesis |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (use within 2 weeks) |
| Molecular Formula | C₁₇H₂₆N₄O₉ (Ala-Glu-Asp-Pro) |
| Molecular Weight | 430.4 Da |
| CAS Number | Available on COA |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Cartalax | 20 mg | 10 vials | ≥98% | In Stock | $94.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
Research has examined cartalax's effects on primary chondrocyte cultures and chondrocyte cell lines (ATDC5, SW1353) in terms of proteoglycan sulfation (DMMB assay), type II collagen immunohistochemistry, and aggrecan mRNA expression. These ECM synthesis endpoints are standard measures of anabolic chondrocyte activity. Research has also examined whether cartalax modulates MMP-13 and ADAMTS-5 — the primary cartilage-degrading enzymes — as an indicator of effects on the anabolic/catabolic balance.
Aging is the primary risk factor for articular cartilage degeneration. Research in aged rodent models has examined cartalax's effects on articular cartilage morphology (safranin-O/fast green staining for proteoglycan content), chondrocyte density in weight-bearing zones, and synovial joint histology. These studies contribute to evaluation of peptide bioregulators as research tools in age-related musculoskeletal biology.
The proposed mechanism of tetrapeptide bioregulators like cartalax involves direct interaction with specific DNA regulatory sequences and chromatin-associated proteins, modulating transcription factor binding in tissue-specific gene promoters. Research probing this mechanism includes chromatin immunoprecipitation (ChIP) studies, gel-shift assays with cartilage-relevant gene promoter sequences, and epigenetic marker changes (H3K4 methylation, histone acetylation) in cartalax-treated chondrocytes.
Cartalax is part of a family of short peptide bioregulators including epithalon (pineal, Ala-Glu-Asp-Gly), pinealon (neural, Glu-Asp-Arg), and thymalin (thymus, polypeptide fraction). Each is proposed to exert tissue-specific gene regulatory effects based on its tissue of origin. Cartalax is the cartilage-derived representative, with research focused on chondrocyte function and ECM biology.
Glucosamine and chondroitin are ECM building block substrates — they provide the structural components for proteoglycan synthesis. Cartalax is proposed to act at the gene regulatory level — modulating transcription of ECM synthesis enzymes and chondrocyte survival genes. They represent mechanistically distinct approaches to cartilage biology research, not interchangeable tools.
Cartalax is synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis from the manufacturing facility is included with every batch.
Lyophilized cartalax should be stored at −20°C. Aqueous solutions should be kept at 2-8°C and used within 2 weeks.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.